柏柏林通过抑制miR-27a分泌来减轻肥胖引起的胰岛素抵抗
Junda Du1,2, Yu Zhu3, Xuehan Yang1
1Department of Pharmacology, College of Basic Medical Sciences, School of nursing, Jilin University, Changchun, Jilin, China.
概括
柏柏林 (BBR) 通过改善代谢参数和抑制miR-27a,有效治疗因肥胖引起的胰岛素抵抗. 这种天然化合物在治疗肥胖和相关并发症方面表现有前途.
科学领域:
- 代谢研究的研究.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 柏柏林 (BBR) 是一种植物性类化合物,具有已知的神经保护性,抗炎性和降脂性.
- 精确的治疗疗效和BBR的潜在机制,特别是在代谢障碍中,需要进一步阐明.
研究的目的:
- 研究柏柏林 (BBR) 对外围组织中因肥胖引起的胰岛素耐药性的治疗作用.
- 阐明BBR对与肥胖相关的代谢功能障碍产生影响的作用机制.
主要方法:
- 高脂肪养和低脂肪养的小鼠与miR-27a过度表达被用BBR (100 mg/kg) 治疗.
- 进行了口服葡萄糖耐受性测试 (OGTT) 和胰岛素耐受性测试 (ITT).
- 在体外实验中,使用BBR (10微米) 治疗棕酸刺激的过敏脂肪细胞,以检查生物化学指标和蛋白质表达.
主要成果:
- 在OGTT和ITT中,BBR干预显著降低了曲线下的面积 (AUC),表明葡萄糖和胰岛素耐受性有所改善.
- 禁食血糖 (FBG),总胆固醇 (TC),甘油三醇 (TG) 和低密度脂蛋白胆固醇 (LDL-C) 的血清水平在BBR治疗后显著下降.
- 在体外,BBR显著降低了过度缩脂肪细胞中的甘油三水平和脂质滴量,同时在体外和体外模型中改善了胰岛素信号通路.
结论:
- 柏柏林 (BBR) 有效地改善肥胖引起的胰岛素抵抗,降低体重,身体脂肪百分比,并改善小鼠的血清生物化学参数.
- BBR通过减少脂肪细胞中的脂质积累和改善胰腺和骨肌肉胰岛素信号来证明其治疗潜力.
- 这项研究表明,BBR的机制涉及抑制miR-27a,这是一种涉及引起胰岛素抵抗的微RNA.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
01:28Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
01:24Obesity
468
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
468
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181